Ignite Creation Date:
2025-12-24 @ 1:36 PM
Ignite Modification Date:
2025-12-28 @ 4:21 AM
Study NCT ID:
NCT00433095
Status:
COMPLETED
Last Update Posted:
2011-03-14
First Post:
2007-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
Sponsor:
Ludwig-Maximilians - University of Munich
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2007-02-07
First Submit QC Date:
None
Study First Post Date:
2007-02-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-03-11
Last Update Post Date:
2011-03-14
Last Update Post Date Type:
ESTIMATED